Search Results
Oct 29, 2025, 01:43 ET BlueNord Announces Third Quarter 2025: Robust Results & Proposed Cash Dividend for the Quarter
Gorm and Halfdan produced 20.2 mboepd during the quarter. Tyra continued its ramp up, averaging 18.9 mboepd during the quarter and reaching its highest average monthly production since restart at 22.0 mboepd in September. As production from the Tyra hub continues to increase, it is making a significant contribution
More news about: BlueNord ASA
Oct 06, 2025, 01:38 ET BlueNord: Preliminary Production for September 2025
BlueNord. The Tyra hub produced 22.0 mboepd net, which is the highest monthly production since the restart of the Tyra facilities. Production stability improved significantly compared to previous months. Efforts to further enhance reliability and performance at Tyra are ongoing, with actions
More news about: BlueNord ASA
Sep 05, 2025, 01:29 ET BlueNord: Preliminary Production for August 2025 and Revised Tyra Guidance
Based on the Tyra performance, BlueNord revises its previously communicated Tyra production guidance for Q3 2025 from 22.0 – 26.0 mboepd to 17.0 – 19.0 mboepd, reflecting July and August production figures and the expected production in September. In addition, the Q4 production guidance for Tyra has also
More news about: BlueNord ASA
Aug 26, 2025, 02:27 ET PPA Tour Asia、マレーシアとベトナムで連続開催のカップ戦を実施
Staksrud選手も金メダル獲得を目指して参戦します。アルゼンチン出身の実力者が太平洋を渡り、アジアのピックルボールの中心地で競い合います。ダブルスの女王Anna Bright選手もマレーシアに登場し、その存在感で大会を大いに盛り上げます。 豪華な顔ぶれは他にも登場し、Tyson McGuffin選手、Tyra Hurricane Black選手、Christian Alshon選手、Zane Navratil選手、Zoey Chao Yi Wang選手、Kaitlyn Christian選手、Alix Truong選手といったスター選手に加え、さらなる人気選手や地元の英雄たちが、パドルを手にして参戦する準備を整えています。
More news about: PPA Tour Asia by UPA Asia
Aug 24, 2025, 21:00 ET PPA亞洲巡迴賽將把背靠背杯賽帶到馬來西亞和越南
一同加入這場爭金之旅的還有男子單打世界排名第一的超級巨星Federico Staksrud。這位阿根廷猛將將橫跨太平洋，前往亞洲匹克球的核心賽場一展身手。此外，雙打女王Anna Bright也將閃耀登場，為馬來西亞賽場帶來火熱激情。 豪華參賽陣容仍在持續壯大：Tyson McGuffin, Tyra Hurricane Black, Christian Alshon, Zane Navratil, Zoey Chao Yi
More news about: PPA Tour Asia by UPA Asia
Aug 21, 2025, 16:05 ET Genpact to Participate in Citi's 2025 Global TMT Conference
Investors Tyra Whelton
More news about: Genpact
Aug 21, 2025, 08:00 ET Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia
Patients page of our website for more information on our clinical trials. About Tyra Biosciences Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large
More news about: Tyra Biosciences
Aug 20, 2025, 16:05 ET Tyra Biosciences Announces Participation at Upcoming Investor Events
website and will be available for replay following the event. About Tyra Biosciences Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large
More news about: Tyra Biosciences
Aug 19, 2025, 17:31 ET FGFR Inhibitors Market Set to Surge by 2034 as Targeted Cancer Therapies Transform Treatment Paradigms | DelveInsight
Emerging FGFR Inhibitors and Companies Promising FGFR inhibitors in the pipeline include TYRA-300 (Tyra Biosciences), ABSK061 (Abbisko Therapeutics), and others. TYRA-300 is an experimental FGFR3 inhibitor engineered for high potency and selectivity, aimed at overcoming
More news about: DelveInsight Business Research, LLP
Aug 14, 2025, 16:05 ET Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights
studies. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced HCC, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma. TYRA is based
More news about: Tyra Biosciences
Aug 08, 2025, 06:22 ET July in Review: 13 Top Health Press Releases
Tyra Biosciences announced details of its abstract to be presented at the meeting. Neurocrine Biosciences sent several ENDO-related announcements, including
More news about: PR Newswire
Aug 07, 2025, 16:05 ET Genpact Reports Second Quarter 2025 Results
Tyra Whelton
More news about: Genpact
Aug 06, 2025, 17:46 ET Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight
UroGen Pharma, Tyra Biosciences, Taiho Oncology, and others, are developing new urothelial carcinoma treatment drugs that can be available in the urothelial carcinoma market in the coming years.The promising urothelial carcinoma therapies in the pipeline include UGN-104, TYRA-300, Futibatinib
More news about: DelveInsight Business Research, LLP
Jul 21, 2025, 16:05 ET Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series
metastatic urothelial cancer. TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. TYRA is based in Carlsbad, CA.
More news about: Tyra Biosciences
Jul 10, 2025, 16:15 ET Genpact Limited Board Declares Quarterly Cash Dividend
Investors Tyra Whelton
More news about: Genpact
Jul 10, 2025, 16:05 ET Genpact to Report Second Quarter 2025 Results
Investors Tyra Whelton
More news about: Genpact
Jul 10, 2025, 09:00 ET Akeneo Introduces First AI Data Architect Agent and New PX Insights Capabilities to Prepare Enterprises for AI-Driven Commerce
"Our agentic AI is purpose-built to solve the single biggest pain point in product data management—modeling," said Andy Tyra, Chief Product Officer, Akeneo. "DAA lets teams design flexible models once and adapt forever, turning product data from a slow-moving liability
More news about: Akeneo
Jul 10, 2025, 01:27 ET BlueNord Announces Second Quarter and First Half 2025: Increased Contribution from Tyra & Proposing Cash Dividend for the Quarter
performance and delivered within guidance. The Tyra ramp-up is progressing well, having reached a peak production rate of c.28 mboe/d net to BlueNord, and the hub is now contributing significantly to the Company's financial results. During the quarter, the Tyra Completion Test under the Reserve Based Lending
More news about: BlueNord ASA
Jul 08, 2025, 16:05 ET Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025
achondroplasia and SURF301 for mUC. TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. TYRA is based in Carlsbad, CA.
More news about: Tyra Biosciences
Jun 30, 2025, 08:00 ET Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
tolerated therapeutic options. TYRA-300 is the only orally administered investigational agent in clinical development for IR NMIBC. About TYRA-300 TYRA-300 is the Company's lead precision medicine program stemming from its in-house SNÅP platform. TYRA-300 is an investigational, oral,
More news about: Tyra Biosciences
Jun 26, 2025, 14:59 ET BlueNord ASA: Successful Placement of Subordinated Hybrid Bond Issue
into the DUC in 2019, while preserving our financial flexibility and removing the equity dilution associated with BNOR15's mandatory conversion. With Tyra fully onstream, we have a robust outlook for both production and cash flow while maintaining a disciplined and resilient balance sheet. This is an
More news about: BlueNord ASA
Jun 26, 2025, 08:05 ET Genpact Unveils GenpactNext Framework and Outlines Medium-Term Targets at 2025 Investor Day
Investors Tyra Whelton +1 (908) 418-2995
More news about: Genpact
Jun 18, 2025, 14:26 ET BlueNord ASA: Announcement of Cash Dividend and Buyback of Shares
2025 where the Company announced its intention to declare a USD 253 million distribution in connection with the Tyra Completion Test being met, as further described therein. Pursuant to the authorization to the board of directors to pay dividends granted by
More news about: BlueNord ASA